

Onychomycosis - Pipeline Insight, 2021

<https://marketpublishers.com/r/O1124E35967DEN.html>

Date: July 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: O1124E35967DEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Onychomycosis - Pipeline Insight, 2021," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Onychomycosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Onychomycosis Understanding

Onychomycosis: Overview

Onychomycosis is fungal infection of the nail plate, nail bed, or both. The nails typically are deformed and discolored white or yellow. Diagnosis is by appearance, wet mount, culture, polymerase chain reaction, or a combination. Treatment, when indicated, is with oral terbinafine or itraconazole. Onychomycosis is suspected by appearance in patients who also have tinea pedis; predictive clinical features include involvement of the 3rd or 5th toenail, involvement of the 1st and 5th toenails on the same foot, and unilateral nail deformity. Subclinical onychomycosis should be considered in patients with recurrent tinea pedis.

'Onychomycosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive

insights of present scenario and growth prospects across the indication. A detailed picture of the Onychomycosis pipeline landscape is provided which includes the disease overview and Onychomycosis treatment guidelines. The assessment part of the report embraces, in depth Onychomycosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Onychomycosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Onychomycosis R&D. The therapies under development are focused on novel approaches to treat/improve Onychomycosis.

Onychomycosis Emerging Drugs Chapters

This segment of the Onychomycosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Onychomycosis Emerging Drugs

MOB?015: Moberg Pharma

MOB?015 is a next?generation treatment for onychomycosis (nail fungus). The high antifungal effect (70-84% mycological cure) demonstrated in two clinical Phase 3 studies, in total including more than 800 patients, indicates that the product has the potential to become the future market leader in nail fungus. License agreements are in place with partners in Europe, Japan, Canada and the Republic of Korea for MOB-015.

BB2603: Blueberry Therapeutics

Blueberry is developing a new topical antifungal spray formulation of terbinafine

(BB2603?om) for the treatment of onychomycosis using our nanodelivery platform technology. The aim is to apply the spray directly to the nail, and through enhanced delivery of the active substance through the nail, to match the cure rates of the more effective oral formulations in a topical medicine, without the associated safety concerns.

Further product details are provided in the report.....

Onychomycosis: Therapeutic Assessment

This segment of the report provides insights about the different Onychomycosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Onychomycosis

There are approx. 12+ key companies which are developing the therapies for Onychomycosis. The companies which have their Onychomycosis drug candidates in the most advanced stage, i.e. phase III include, Moberg Pharma.

Phases

DelveInsight's report covers around 12+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Onychomycosis pipeline report provides the therapeutic assessment of the pipeline

drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intradermal

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Onychomycosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Onychomycosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Onychomycosis drugs.

Onychomycosis Report Insights

Onychomycosis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Onychomycosis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Onychomycosis drugs?

How many Onychomycosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Onychomycosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Onychomycosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Onychomycosis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Moberg Pharma

Blueberry Therapeutics

DermBiont

Sanotize Research and Development

Meiji Seika Pharma

NovaBiotics

Polichem

Hallux

Hexima

Turn Therapeutics

9305-9954 Quebec

Mycovia Pharmaceuticals

CSA BioTech

Kaken Pharmaceutical

Turn Therapeutics

Key Products

MOB?015

BB-2603

DBI 001

NORS 6491

ME 1111

NP 213

ALM-12834

HTS-519

HXP 124

GX-03

CELEXT 07

VT-1161

KP-607

Contents

Introduction

Executive Summary

Onychomycosis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

MOB?015: Moberg Pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

BB2603: Blueberry Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

KP-607: Kaken Pharmaceutical

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
 Comparative Analysis
GX-03: Turn Therapeutics
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....

Inactive Products
 Comparative Analysis
Onychomycosis Key Companies
Onychomycosis Key Products
Onychomycosis- Unmet Needs
Onychomycosis- Market Drivers and Barriers
Onychomycosis- Future Perspectives and Conclusion
Onychomycosis Analyst Views
Onychomycosis Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Onychomycosis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Onychomycosis

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Onychomycosis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/O1124E35967DEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O1124E35967DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970